Close

Seres Therapeutics (MCRB) Achieves Target Enrollment of SER-109 Phase 2 Study

May 2, 2016 8:03 AM EDT Send to a Friend
Seres Therapeutics, Inc. (NASDAQ: MCRB) announced today that the target enrollment of 87 patients has been achieved for its ongoing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login